FRANKFURT (dpa-AFX) - As in December, investors at Bayer continue to bet on better times again at the start of the year. The pharmaceutical and agrochemical company was the third-largest DAX loser in 2023, losing a good 30 percent of its value. With an increase of 2.3 percent on Thursday, it was not only the leader in the DAX, but also recorded its 13th consecutive day of gains. The last time there was a one-day loss was in mid-December.

Since approaching the 30-euro mark at the end of November in the wake of new bad news from two divisions, the shares have now gained 18 percent in value again.

On Thursday, the interim results of a trial with a Parkinson's drug, in which a primary endpoint was reached, fit into the mood of hope for better times.

In November, a new low in the US glyphosate dispute and the discontinuation of a clinical trial with the pharmaceutical hopeful Asundexian pushed the shares to a seventeen-year low. The shares only started to turn around at the low point in 2006. Recently, split-up scenarios have also been played out at Bayer and on the market./tih/jha/